Prescribing information

 

Please contact a Novartis representative to order these materials.

*In a post-hoc analysis of Phase III studies (ASTERIA I & II and GLACIAL), omalizumab 300 mg significantly improved total DLQI scores vs placebo; – ASTERIA I : mean decrease from baseline to Week 12 of -10.3 vs -6.1 (p<0.0001), – ASTERIA II : -10.2 vs -6.1 (p=0.0004), –  GLACIAL : -9.7 vs -5.1 (p<0.0001).1
Patients with no known history of anaphylaxis may self-inject Xolair or be injected by a caregiver from the 4th dose onwards if a physician determines that this is appropriate. The patient or the caregiver must have been trained in the correct injection technique and the recognition of the early signs and symptoms of serious allergic reactions.2

References

  1. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721
  2. Xolair® (omalizumab) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | April 2022 | 164038
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]